Vertex stock slumped Tuesday despite notching a definitive beat for its Crispr-partnered blood diseases gene editor, Casgevy.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead ·
Investor's Business Daily
